| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| MNKDMannKind Corporation | 1.71B | 5.58 | 57.41 | 43.5% | 9.32% | 1.92% | ||
| CORTCorcept Therapeutics Incorporated | 3.72B | 35.39 | 28.77 | 39.94% | 14.19% | 16.65% | 5.26% | 0.01 |
| GUTSFractyl Health, Inc. Common Stock | 302.14M | 1.97 | -1.22 | -22.5% | -40732.33% | -241.68% | 2.20 | |
| LXRXLexicon Pharmaceuticals, Inc. | 465.15M | 1.28 | -2.03 | 24.81% | -96.77% | -57.07% | 0.74 | |
| RZLTRezolute, Inc. | 260.56M | 2.81 | -2.87 | -52.45% | 0.01 | |||
| MISTMilestone Pharmaceuticals Inc. | 172.89M | 2.03 | -3.03 | -100% | -282.97% | 4.17 | ||
| ALTAltimmune, Inc. | 442.41M | 4.24 | -3.16 | -95.31% | -4195.75% | -45.21% | 0.01 | |
| BIOABioAge Labs, Inc. | 771.24M | 21.51 | -3.24 | -12.81% | -27.32% | 0.03 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 589K | 2.04M | 2.43M | 1.19M | 71K | 1.08M | 4.74M | 4.01M | 1.04M |
| Revenue Growth % | - | 2.47% | 0.19% | -0.51% | -0.94% | 14.18% | 3.39% | -0.15% | -0.74% |
| Cost of Goods Sold | 5.1M | 9.23M | 24.48M | 1.11M | 57M | 0 | 0 | 0 | 2.79M |
| COGS % of Revenue | 8.66% | 4.51% | 10.08% | 0.93% | 802.79% | - | - | - | 2.68% |
| Gross Profit | -4.51M | -7.19M | -22.05M | 80K | -56.93M | 1.08M | 4.74M | 4.01M | -1.75M |
| Gross Margin % | -7.66% | -3.51% | -9.08% | 0.07% | -801.79% | 1% | 1% | 1% | -1.68% |
| Gross Profit Growth % | - | -0.59% | -2.07% | 1% | -712.59% | 1.02% | 3.39% | -0.15% | -1.44% |
| Operating Expenses | 6.04M | 9.13M | 28.71M | 53.83M | 18.03M | 108.78M | 172.62M | 226.62M | 337.11M |
| OpEx % of Revenue | 10.26% | 4.46% | 11.82% | 45.12% | 253.89% | 100.91% | 36.44% | 56.47% | 324.45% |
| Selling, General & Admin | 1.53M | 1.94M | 6.66M | 13.52M | 18.03M | 24.52M | 42.39M | 58.09M | 99.74M |
| SG&A % of Revenue | 2.6% | 0.95% | 2.74% | 11.33% | 253.89% | 22.75% | 8.95% | 14.48% | 95.99% |
| Research & Development | 5.1M | 9.23M | 24.48M | 41.51M | 57.6M | 84.25M | 130.22M | 168.53M | 240.16M |
| R&D % of Revenue | 8.66% | 4.51% | 10.08% | 34.79% | 811.24% | 78.16% | 27.49% | 42% | 231.14% |
| Other Operating Expenses | -1K | -48K | 1.59M | -1.19M | -57.6M | 0 | 0 | 0 | -2.79M |
| Operating Income | -6.04M | -9.13M | -28.71M | -53.83M | -74.95M | -107.7M | -167.88M | -222.61M | -338.85M |
| Operating Margin % | -10.26% | -4.46% | -11.82% | -45.12% | -1055.68% | -99.91% | -35.44% | -55.47% | -326.13% |
| Operating Income Growth % | - | -0.51% | -2.15% | -0.88% | -0.39% | -0.44% | -0.56% | -0.33% | -0.52% |
| EBITDA | -5.95M | -9M | -28.24M | -52.72M | -74M | -106.78M | -166.9M | -221.51M | -336.07M |
| EBITDA Margin % | -10.11% | -4.4% | -11.63% | -44.19% | -1042.32% | -99.05% | -35.23% | -55.2% | -323.45% |
| EBITDA Growth % | - | -0.51% | -2.14% | -0.87% | -0.4% | -0.44% | -0.56% | -0.33% | -0.52% |
| D&A (Non-Cash Add-back) | 92K | 128K | 471K | 1.11M | 948K | 922K | 983K | 1.1M | 2.79M |
| EBIT | -6.01M | -9.15M | -27.11M | -53.83M | -74.95M | -107.7M | -167.88M | -222.61M | -338.85M |
| Net Interest Income | 26K | 18K | 0 | 3.46M | 991K | 157K | 4.32M | 13.44M | 41.44M |
| Interest Income | 37K | 26K | 1.75M | 3.46M | 991K | 157K | 4.32M | 13.44M | 41.44M |
| Interest Expense | 11K | 8K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 25K | -30K | 1.59M | 3.41M | 1.14M | 61K | 3.96M | 8.08M | 40.45M |
| Pretax Income | -6.02M | -9.16M | -27.11M | -50.42M | -73.81M | -107.64M | -163.92M | -214.53M | -298.41M |
| Pretax Margin % | -10.22% | -4.48% | -11.17% | -42.26% | -1039.61% | -99.85% | -34.6% | -53.46% | -287.21% |
| Income Tax | 10K | -40K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 0.98% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -6.02M | -9.16M | -27.11M | -49.53M | -73.81M | -107.64M | -163.92M | -214.53M | -298.41M |
| Net Margin % | -10.22% | -4.48% | -11.17% | -41.52% | -1039.61% | -99.85% | -34.6% | -53.46% | -287.21% |
| Net Income Growth % | - | -0.52% | -1.96% | -0.83% | -0.49% | -0.46% | -0.52% | -0.31% | -0.39% |
| Net Income (Continuing) | -6.02M | -9.16M | -27.11M | -50.42M | -73.81M | -107.64M | -163.92M | -214.53M | -298.41M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.43 | -0.66 | -2.23 | -2.05 | -2.42 | -2.80 | -3.15 | -3.69 | -3.69 |
| EPS Growth % | - | -0.53% | -2.38% | 0.08% | -0.18% | -0.16% | -0.13% | -0.17% | 0% |
| EPS (Basic) | -0.43 | -0.66 | -2.23 | -2.05 | -2.42 | -2.80 | -3.15 | -3.69 | -3.69 |
| Diluted Shares Outstanding | 13.88M | 13.88M | 12.14M | 24.18M | 30.45M | 38.44M | 51.98M | 58.07M | 80.78M |
| Basic Shares Outstanding | 13.88M | 13.88M | 12.14M | 24.18M | 30.45M | 38.44M | 51.98M | 58.07M | 80.78M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 12.37M | 15.16M | 166.68M | 123.34M | 177.49M | 344.72M | 345.18M | 574.15M | 1.38B |
| Cash & Short-Term Investments | 12.15M | 14.19M | 163.88M | 118.39M | 170.88M | 333.71M | 334.43M | 558.55M | 1.35B |
| Cash Only | 12.15M | 14.19M | 44.97M | 40.33M | 93.09M | 200.69M | 32.67M | 54.9M | 264.55M |
| Short-Term Investments | 0 | 0 | 118.9M | 78.07M | 77.79M | 133.01M | 301.75M | 503.66M | 1.09B |
| Accounts Receivable | 72K | 734K | 0 | 1.38M | 1.83M | 2.03M | 2.42M | 9.35M | 8.47M |
| Days Sales Outstanding | 44.62 | 131.01 | - | 421.6 | 9.42K | 687 | 186.85 | 850.51 | 2.98K |
| Inventory | 98K | 141K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 7.01 | 5.57 | - | - | - | - | - | - | - |
| Other Current Assets | 43K | 0 | 0 | 1.09M | 1.02M | 0 | 2.54M | 1.58M | 1.71M |
| Total Non-Current Assets | 234K | 433K | 4.73M | 7.04M | 5.95M | 6.29M | 6.99M | 61.2M | 59.2M |
| Property, Plant & Equipment | 224K | 400K | 4.23M | 6.46M | 5.41M | 4.72M | 4.99M | 57.43M | 55.58M |
| Fixed Asset Turnover | 2.63x | 5.11x | 0.57x | 0.18x | 0.01x | 0.23x | 0.95x | 0.07x | 0.02x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 500K | 500K | 0 | 1.01M | 1.97M | 1.77M | 800K |
| Other Non-Current Assets | 10K | 33K | 0 | 82K | 540K | 568K | 37K | 2M | 2.83M |
| Total Assets | 12.6M | 15.6M | 171.41M | 130.38M | 183.44M | 351.01M | 352.18M | 635.35M | 1.43B |
| Asset Turnover | 0.05x | 0.13x | 0.01x | 0.01x | 0.00x | 0.00x | 0.01x | 0.01x | 0.00x |
| Asset Growth % | - | 0.24% | 9.99% | -0.24% | 0.41% | 0.91% | 0% | 0.8% | 1.26% |
| Total Current Liabilities | 890K | 897K | 7.92M | 8.34M | 10.49M | 15.99M | 27.72M | 43.94M | 59.68M |
| Accounts Payable | 340K | 403K | 1.46M | 2.7M | 3.49M | 3.42M | 6.88M | 6.55M | 5.85M |
| Days Payables Outstanding | 24.33 | 15.93 | 21.71 | 884.79 | 22.34 | - | - | - | 767.09 |
| Short-Term Debt | 49K | 0 | 0 | 724K | 0 | 0 | 1.05M | 4.17M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 1000K | 1000K | 1000K |
| Other Current Liabilities | 0 | 0 | 590K | 2.8M | 4.9M | 7.53M | 8.47M | 16.65M | 10K |
| Current Ratio | 13.89x | 16.91x | 21.03x | 14.79x | 16.92x | 21.55x | 12.45x | 13.07x | 23.04x |
| Quick Ratio | 13.78x | 16.75x | 21.03x | 14.79x | 16.92x | 21.55x | 12.45x | 13.07x | 23.04x |
| Cash Conversion Cycle | 27.3 | 120.65 | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 17.91M | 29.72M | 3.27M | 4.9M | 4.04M | 3.08M | 8.13M | 52.3M | 50.1M |
| Long-Term Debt | 163K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 4.85M | 4.01M | 3.07M | 2.02M | 47.55M | 44.57M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 17.75M | 29.72M | 3.27M | 49K | 23K | 2K | 0 | 0 | 829K |
| Total Liabilities | 18.8M | 30.62M | 11.19M | 13.24M | 14.53M | 19.07M | 35.85M | 96.25M | 109.79M |
| Total Debt | 212K | 0 | 0 | 5.57M | 4.01M | 3.07M | 3.08M | 51.73M | 51.72M |
| Net Debt | -11.94M | -14.19M | -44.97M | -34.75M | -89.07M | -197.62M | -29.6M | -3.17M | -212.82M |
| Debt / Equity | - | - | - | 0.05x | 0.02x | 0.01x | 0.01x | 0.10x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -549.45x | -1140.88x | - | - | - | - | - | - | - |
| Total Equity | -6.2M | -15.02M | -43.38M | 117.14M | 168.92M | 331.94M | 316.33M | 539.11M | 1.32B |
| Equity Growth % | - | -1.42% | -1.89% | 3.7% | 0.44% | 0.97% | -0.05% | 0.7% | 1.46% |
| Book Value per Share | -0.45 | -1.08 | -3.57 | 4.85 | 5.55 | 8.64 | 6.09 | 9.28 | 16.40 |
| Total Shareholders' Equity | -6.2M | -15.02M | -43.38M | 117.14M | 168.92M | 331.94M | 316.33M | 539.11M | 1.32B |
| Common Stock | 1K | 1K | 24K | 210.79M | 336.51M | 607.58M | 759.43M | 1.19B | 2.28B |
| Retained Earnings | -7.11M | -16.27M | -43.38M | -93.8M | -167.61M | -275.25M | -439.17M | -653.7M | -952.11M |
| Treasury Stock | 0 | 0 | -374.94M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -182K | -304K | 61K | 148K | 25K | -382K | -3.93M | 977K | 963K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -5.47M | -9.48M | -19.46M | -46.38M | -62.03M | -88.59M | -115.2M | -166.31M | -225.97M |
| Operating CF Margin % | -9.28% | -4.64% | -8.01% | -38.88% | -873.62% | -82.18% | -24.32% | -41.44% | -217.49% |
| Operating CF Growth % | - | -0.73% | -1.05% | -1.38% | -0.34% | -0.43% | -0.3% | -0.44% | -0.36% |
| Net Income | -6.02M | -9.16M | -27.11M | -50.42M | -73.81M | -107.64M | -163.92M | -214.53M | -298.41M |
| Depreciation & Amortization | 92K | 128K | 471K | 887K | 948K | 922K | 983K | 1.1M | 2.79M |
| Stock-Based Compensation | 270K | 271K | 2.32M | 6.29M | 10.43M | 17.35M | 28.27M | 40.94M | 69.39M |
| Deferred Taxes | 0 | 0 | 0 | -1.23M | -227K | 422K | 0 | 0 | 0 |
| Other Non-Cash Items | 154K | 480K | -433K | 222K | 261K | -739K | 850K | -1.86M | -11.37M |
| Working Capital Changes | 189K | -721K | 5.3M | -2.13M | 376K | 1.1M | 18.61M | 8.04M | 11.63M |
| Change in Receivables | 0 | 0 | 0 | 0 | 2.72M | 6.29M | 10.99M | 14.65M | 17.54M |
| Change in Inventory | 0 | 0 | 0 | 0 | -2.72M | -6.29M | 0 | 0 | 0 |
| Change in Payables | 300K | 47K | 7.36M | 696K | 2.72M | 6.29M | 0 | 0 | 0 |
| Cash from Investing | -190K | -304K | -119.46M | 41.67M | 217K | -56.48M | -173.98M | -200.41M | -574.82M |
| Capital Expenditures | -190K | -304K | -1.06M | -492K | -186K | -436K | -1.66M | -4.69M | -3.84M |
| CapEx % of Revenue | 0.32% | 0.15% | 0.44% | 0.41% | 2.62% | 0.4% | 0.35% | 1.17% | 3.7% |
| Acquisitions | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -118.4M | 1.23M | 227K | -422K | 0 | 0 | 0 |
| Cash from Financing | -53K | 11.82M | 170.2M | 67K | 114.57M | 252.68M | 121.96M | 388.94M | 1.01B |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - |
| Other Financing | -5K | 66K | 451K | 126K | 288K | 3.14M | 4.72M | 19.93M | 40.39M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -5.66M | -9.78M | -20.52M | -46.87M | -62.21M | -89.02M | -116.86M | -171M | -229.81M |
| FCF Margin % | -9.61% | -4.78% | -8.45% | -39.29% | -876.24% | -82.58% | -24.67% | -42.61% | -221.19% |
| FCF Growth % | - | -0.73% | -1.1% | -1.28% | -0.33% | -0.43% | -0.31% | -0.46% | -0.34% |
| FCF per Share | -0.41 | -0.70 | -1.69 | -1.94 | -2.04 | -2.32 | -2.25 | -2.94 | -2.84 |
| FCF Conversion (FCF/Net Income) | 0.91x | 1.04x | 0.72x | 0.94x | 0.84x | 0.82x | 0.70x | 0.78x | 0.76x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -134.32% | -51.61% | -42.98% | -50.57% | -50.16% | -32.02% |
| Return on Invested Capital (ROIC) | - | - | - | - | -69.3% | -75.43% | -59.81% | -40.59% | -30.84% |
| Gross Margin | -765.87% | -351.49% | -908.2% | 6.71% | -80178.87% | 100% | 100% | 100% | -168.05% |
| Net Margin | -1021.9% | -447.78% | -1116.76% | -4152.14% | -103960.56% | -9985.25% | -3460.38% | -5345.85% | -28720.69% |
| Debt / Equity | - | - | - | 0.05x | 0.02x | 0.01x | 0.01x | 0.10x | 0.04x |
| Interest Coverage | -549.45x | -1140.88x | - | - | - | - | - | - | - |
| FCF Conversion | 0.91x | 1.04x | 0.72x | 0.94x | 0.84x | 0.82x | 0.70x | 0.78x | 0.76x |
| Revenue Growth | - | 247.2% | 18.73% | -50.86% | -94.05% | 1418.31% | 339.42% | -15.28% | -74.11% |
Crinetics Pharmaceuticals, Inc. (CRNX) reported $1.5M in revenue for fiscal year 2024. This represents a 161% increase from $0.6M in 2016.
Crinetics Pharmaceuticals, Inc. (CRNX) saw revenue decline by 74.1% over the past year.
Crinetics Pharmaceuticals, Inc. (CRNX) reported a net loss of $423.1M for fiscal year 2024.
Crinetics Pharmaceuticals, Inc. (CRNX) has a return on equity (ROE) of -32.0%. Negative ROE indicates the company is unprofitable.
Crinetics Pharmaceuticals, Inc. (CRNX) had negative free cash flow of $356.0M in fiscal year 2024, likely due to heavy capital investments.